Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Lee430on Jun 07, 2021 6:49pm
143 Views
Post# 33345151

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Weekly Report Card

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Weekly Report CardScarlet1967,
I would like to personally thank you for all of your efforts to guide & persuade Thera/Leah to embrace the obvious need to court the retail investor, unfortunately you have led the horse to water but is not even aware it’s thirsty….VERY frustrating!!


scarlet1967 wrote:

This was posted by Spceo earlier and it is what’s has has been happening for quite a while, the company paid almost $2 M to bring Paul a marketing guy let him do what he is supposed to do, sell the company.

I think he is restrained by a board which is comfortable with their way of conducting the business. Re-engineer their mindset would be a start. For almost two years I have been screaming at company to take advantage of powerful retail investors in the stock market followed by many sent emails and a good half an hour of eating Leah’s brain..get the rebranding started by approaching the retail. Today thanks to biogen’s approval which showed the agency is more flexible than many anticipated the NBI was up over 3% especially the NASH stock but hey we aren’t a NASH phase whatever company!

 

 Aron is part of a growing number of executives on Wall Street such as Tesla Inc's (TSLA.O) Elon Musk and the incoming chairman of GameStop Corp (GME.N), Ryan Cohen, who appear to be doing more to court retail rather than institutional investors.

 

Promoting a company's shares to retail investors may be the new reality for many companies, said Jim Paulsen, chief investment officer at the Leuthold Group.

 

"CEOs have always been showmen and a big part of what they do is put on shows for institutional investors," said Paulsen. "You may have a Reddit group that is the focus of the tweet but the reality is institutional guys like me are going to hear about it just as quickly."

 

https://www.reuters.com/business/with-popcorn-tweets-amcs-aron-rides-retail-investor-wave-2021-06-03/



<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse